Nicollet Investment Management Inc. Invests $4.72 Million in Boston Scientific Corporation $BSX

Nicollet Investment Management Inc. purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the fourth quarter, Holdings Channel.com reports. The fund purchased 49,525 shares of the medical equipment provider’s stock, valued at approximately $4,722,000. Boston Scientific makes up about 1.5% of Nicollet Investment Management Inc.’s portfolio, making the stock its 21st biggest position.

A number of other hedge funds and other institutional investors have also made changes to their positions in BSX. Brighton Jones LLC increased its holdings in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares during the last quarter. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Main Street Financial Solutions LLC increased its holdings in shares of Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after buying an additional 1,971 shares during the last quarter. Ieq Capital LLC increased its holdings in shares of Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after buying an additional 60,860 shares during the last quarter. Finally, HUB Investment Partners LLC increased its holdings in Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after purchasing an additional 2,556 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of several research reports. Truist Financial dropped their target price on shares of Boston Scientific from $85.00 to $64.00 and set a “buy” rating for the company in a report on Thursday, June 4th. Oppenheimer set a $90.00 target price on shares of Boston Scientific in a report on Thursday, April 23rd. UBS Group dropped their target price on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Boston Scientific in a report on Thursday, May 28th. Finally, Wolfe Research downgraded shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $85.92.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David C. Habiger purchased 2,250 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig purchased 3,580 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the transaction, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 9,800 shares of company stock valued at $554,012 in the last 90 days. Company insiders own 0.34% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $48.42 on Thursday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 52 week low of $47.17 and a 52 week high of $109.50. The stock has a market capitalization of $71.98 billion, a PE ratio of 20.26, a P/E/G ratio of 0.92 and a beta of 0.56. The firm has a 50 day moving average of $56.99 and a two-hundred day moving average of $75.49.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter last year, the company posted $0.75 EPS. The firm’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its board has initiated a stock buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its shares are undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.